ADAPTIMMUNE
Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroys cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.
ADAPTIMMUNE
Industry:
Biopharma Biotechnology Health Care Medical
Founded:
2008-01-01
Address:
Oxton, York, United Kingdom
Country:
United Kingdom
Website Url:
http://www.adaptimmune.com
Total Employee:
251+
Status:
Active
Contact:
+1 (215) 825 9260
Email Addresses:
[email protected]
Total Funding:
399.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Google Universal Analytics
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Agenus
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Healx
Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Kuros Biosciences
Kuros Biosurgery develops biomaterials and bioactive biomaterial combination products for indications in trauma, wound and spine.
Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Theravectys
Theravectys develops a platform for the prevention and treatment of cancers and other infectious diseases and conditions.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Genentech
Genentech investment in Post-IPO Equity - Adaptimmune
Eight Roads Ventures
Eight Roads Ventures investment in Venture Round - Adaptimmune
Merlin Nexus
Merlin Nexus investment in Series A - Adaptimmune
F-Prime Capital
F-Prime Capital investment in Series A - Adaptimmune
Wellington Management
Wellington Management investment in Series A - Adaptimmune
Ridgeback Capital
Ridgeback Capital investment in Series A - Adaptimmune
University of Oxford
University of Oxford investment in Series A - Adaptimmune
Foresite Capital
Foresite Capital investment in Series A - Adaptimmune
Novo Holdings
Novo Holdings investment in Series A - Adaptimmune
venBio Partners
venBio Partners investment in Series A - Adaptimmune
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-26 | Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer |
Official Site Inspections
http://www.adaptimmune.com Semrush global rank: 2.44 M Semrush visits lastest month: 7.35 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Adaptimmune" on Search Engine
Engagement with Patient Organizations :: Adaptimmune (ADAP)
Engagement with Patient Organizations. Adaptimmune is driven by a mission to transform the lives of people with cancer by designing and delivering cell therapies. Patient …See details»
Our Company :: Adaptimmune (ADAP)
Overview. Partners. Board of Directors. Leadership Team. The personal nature of our science and our drive is supported by the perseverance to successfully discover, …See details»
Adaptimmune | LinkedIn
Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its …See details»
Adaptimmune | LinkedIn
Adaptimmune | LinkedIn. Biotechnology Research. Abingdon, Oxfordshire 44,099 followers. Designing and delivering cell therapies to transform the lives of people with cancer. View all 503...See details»
Adaptimmune Enters into a Strategic Collaboration with
Sep 7, 2021 PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in …See details»
Adaptimmune Announces Clinical Responses across Five Solid
Sep 13, 2021 PHILADELPHIA and OXFORD, U.K., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat …See details»
Interview with the CEO: Adaptimmune Therapeutics PLC …
August 22, 2022. Adrian “Ad” Rawcliffe, CEO, Adaptimmune (ADAP) Word count: 2,971. TWST: Let’s start with an overview of the company, its history and how it has evolved …See details»
Adaptimmune Reports Q4/Full Year 2023 Financial Results and …
Mar 6, 2024 Philadelphia, Pennsylvania and Oxford, United Kindgom-- (Newsfile Corp. - March 6, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company …See details»
Strategic Collaboration between Adaptimmune and Genentech to …
Apr 12, 2024 Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - April 12, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company …See details»
Adaptimmune Reports Q4/Full Year 2023 Financial Results and …
Mar 6, 2024 Philadelphia, Pennsylvania and Oxford, United Kindgom-- (Newsfile Corp. - March 6, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company …See details»
Adaptimmune Announces U.S. FDA Acceptance of Biologics …
Jan 31, 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom-- (Newsfile Corp. - January 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company …See details»
Adaptimmune Enters into a Strategic Collaboration with …
Sep 7, 2021 PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in …See details»
Perspectives :: Adaptimmune (ADAP)
Read perspectives from our colleagues and external experts on our work and how we are improving cancer patients’ lives.See details»
Strategic Collaboration between Adaptimmune and Genentech to …
Apr 12, 2024 Philadelphia, Pennsylvania and Oxford, United Kindgom-- (Newsfile Corp. - April 12, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company …See details»
Adaptimmune - Crunchbase Company Profile & Funding
Legal Name Adaptimmune Limited. Stock Symbol NASDAQ:ADAP. Company Type For Profit. Contact Email [email protected]. Phone Number +1 (215) 825 9260. …See details»
Adaptimmune Submits Afami-Cel First Engineered TCR-T …
Dec 6, 2023 1. Adaptimmune completes submission of rolling biologics license application (BLA) to U.S. FDA for afami-cel for the treatment of advanced synovial sarcoma. News …See details»
New Executive Team Announced at Adaptimmune - Pharma's …
Aug 6, 2019 PHILADELPHIA and OXFORDSHIRE, United Kingdom, (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell …See details»
Adaptimmune - Funding, Financials, Valuation & Investors
Funding. Adaptimmune has raised a total of. $474.5M. in funding over 8 rounds. Their latest funding was raised on Sep 7, 2021 from a Post-IPO Equity round. Adaptimmune …See details»
Adaptimmune Announces U.S. FDA Acceptance of Biologics …
Jan 31, 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom-- (Newsfile Corp. - January 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company …See details»
Adaptimmune - Contacts, Employees, Board Members, Advisors …
Organization. Adaptimmune. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 13. Number of Board …See details»